UBS Downgrades Jazz Pharmaceuticals to Neutral, Lowers Price Target to $135
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma downgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) from Buy to Neutral and reduced the price target from $170 to $135.
November 27, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS downgraded Jazz Pharmaceuticals from Buy to Neutral and lowered the price target from $170 to $135, potentially impacting investor sentiment.
Analyst downgrades typically lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The reduction in the price target further suggests a lower expected future performance, which may also negatively influence the stock's short-term movement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100